Colorectal Cancer Metastatic
Conditions
Keywords
Metronomic Chemotherapy, Anti-Angiogenic, Maintenance Treatment, Colorectal Cancer Metastatic
Brief summary
Colorectal cancer patients with metastases (mCRC) at response under expensive chemotherapy which may be toxic +/- exhausting are candidates for an effective and more convenient maintenance treatment. Objectives: 1. To define the efficacy of maintenance chemotherapy by a low-dose metronomic (LDM) regimen, in metastatic CRC patients responding under FOLFIRI + bevacizumab. 2. To discover predictive factors for response to this LDM regimen. Hypothesis: 1. The re-growth of residual metastases can be slowed by the anti-angiogenic effects of LDM chemotherapy. 2. Serial measurements of angiogenic/ inflammatory factors in the plasma and/or evaluation of certain enzymes in the tumor may discover predictive factors of response to LDM chemotherapy in metastatic CRC patients.
Detailed description
At entry to the research protocol the up-till then administered treatment with Intra Venous FOLFIRI+BEVACIZUMAB will be stopped.Instead, the research oral treatment will be initiated to be taken daily on an ambulatory basis and under once monthly re-evaluation. If and when disease progresses the original FOLFIRI+BEVACIZUMAB treatment will be considered for re-institution.
Interventions
DRUGCAPECITABINE, CELECOXIB and METHOTREXATE
daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
Sponsors
Clalit Health Services
HaEmek Medical Center, Israel
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Histologic (or cytologic) proof of colorectal carcinoma (CRC). 2. Age: between 18 and 80. 3. Sex: both sexes. 4. Previous treatment for metastatic disease is limited to FOLFIRI+ bevacizumab. 5. Prior adjuvant chemotherapy, with a fluoropyrimidine and/or Oxaliplatin, is allowed. 6. Prior radiotherapy, either as adjuvant treatment or palliation of metastatic sites is allowed, provided that there are other non-irradiated foci of disease for evaluation. 7. Persistent remission, either complete, partial or minimal response (CR, PR or MR) or stable disease (SD), one year+/-one month from initiation of first line treatment for mCRC. 8. Asymptomatic patients at break from chemotherapy. 9. Intact organ function, including complete blood counts (CBC) showing normal values or any toxicity limited to grade 1 and blood chemistry (SMA) showing liver and renal functions \< 1.5 upper normal limit (UNL). 10. Capability to understand and to sign the informed consent.
Exclusion criteria
1. Concurrent any other cancer (except BCC or squamous cell carcinoma of skin). 2. Inability to adhere to monthly visits to the oncology unit for evaluation. 3. Presence of brain metastases. 4. Any current or recent (within the last month) continuous treatment by steroids or by NSAIDs, or with therapeutic doses of anticoagulants for any reason. 5. Previous radiotherapy to the only site of measurable disease. 6. Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac including arrhythmias, hepatic or renal disease), and/or existence of active peptic ulcer (clinically and/or by gastroscopy).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Length of progression free survival (PFS), measured in months. | Up to 12 months. | From start of the experimental treatment until the date of first documented progression or date of death of any cause,whichever came first, assessed up to 12 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity profile of treatment, defined by CTCAE Version 4.0. | up to12 months | From start of the experimental treatment until the date of first documented progression or date of death of any cause,whichever came first, assessed up to 12 months. |
| Changes in levels of angiogenic factors while under treatment: VEGF, PDGF, TSP-1 | Up to 4 months. | Change from baseline in levels of angiogenic factors at 4 months of treatment. |
| Quality of life, as expressed by FACT-C. | Up to 12 months. | Change from baseline in parameters of Quality of life until the end of treatment, assessed up to 12 months. |
Countries
Israel
Outcome results
None listed